New PET scans could predict who benefits from targeted breast cancer therapy
NCT ID NCT07471776
First seen Mar 17, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study tests whether two types of PET scans can predict how well a targeted therapy works in people with advanced HER2-negative breast cancer. The therapy, called a TROP2 antibody-drug conjugate, delivers chemotherapy directly to cancer cells. Researchers will scan 45 participants before treatment to see if imaging can forecast outcomes. The goal is to develop a prediction model that helps doctors choose the right treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab Govitecan, Datopotamab deruxtecan, Sacituzumab tirumotecan (TROP2-targeted antibody-drug conjugates)
What this could lead to
If successful, this could help doctors predict which patients will benefit from TROP2-targeted therapies, making treatment more personalized and effective.
What could go wrong
This is a small, early-phase study focused on imaging prediction, not treatment outcomes. The prediction model may not prove accurate enough for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.